ArticleTherapeutic advances in gastrointestinal endoscopy
EUS-guided radiofrequency and ethanol ablation of pancreatic insulinomas: a single-center experience.
Article in Therapeutic advances in gastrointestinal endoscopy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical outcomes of medical therapy, EUS-guided ethanol ablation, and surgical resection in insulinoma: a clinical epidemiology study.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Insulinomas are the most common functional pancreatic neuroendocrine tumors (pNETs). Minimally invasive approaches like endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) and ethanol ablation (EUS-EA) are emerging treatment options for small insulinomas (<2 cm). Objectives: To assess the safety, efficacy, and long-term outcomes of EUS-RFA and EUS-EA in treating small pancreatic insulinomas. Design: A retrospective, single-center study of nine patients diagnosed with insulinomas and treated with EUS ablation methods. Methods: Nine lesions (mean size 11 mm; range: 6-19 mm) were treated with EUS-RFA ( Results: All patients had immediate hypoglycemia relief after a single treatment. The median clinical follow-up was 40 months (range: 22-60 months), with all patients remaining asymptomatic. Complete radiologic regression was observed in six patients. Two patients had minor adverse events; no severe complications occurred. Conclusion: EUS-guided ablation (RFA or EA) is a safe and effective treatment for small pancreatic insulinomas, providing symptom relief and radiologic regression. Further studies are needed to evaluate long-term efficacy and recurrence rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.